Intellia Therapeutics announces first patient dosed in the HAELO Phase 3 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema
Intellia Therapeutics announced that the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of HAE. Intellia expects to complete enrollment in the second half of 2025 and submit a biologics license application (BLA) in 2026 to support the Company’s plans for a US launch in 2027.
Intellia President and Chief Executive Officer John Leonard MD, said: “We are pleased to have initiated dosing in the HAELO Phase 3 study as we are in our final lap of clinical development for NTLA-2002. With the promising data we’ve presented thus far, we believe patients could achieve independence from both HAE attacks and medications required to treat this disease. We look forward to presenting longer-term data from the ongoing Phase 1/2 study later this year highlighting the durability of effect of NTLA-2002.”
Dr Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research Inc, commented: “We are excited to have treated the first patient in the US with a new generation of therapy that could potentially provide patients with lifelong relief from the primary symptoms of HAE.”
(Source: Intellia)
